Articles On Imagion Biosystems (ASX:IBX)

Summary The RLC share price has shot up by a massive 68.7% to AU$0.027 in today’s session. Mosaic Brands has successfully completed a series of strategic initiatives. The WAK share price has shot up 13.5% to AU$0.21 as the company sig...

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s b...

Summary Medicinal cannabis player Botanix Pharmaceuticals Limited has provided a clinical development update of the BTX 1801 antimicrobial platform. Botanix’s BTX 1801 was safe, well-tolerated, clinically effective in the Phase 2a stud...

Funds management administration company Mainstream Group (ASX:MAI) topped the Running Hot list with a 14-day RSI of 92 this week. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI)....

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Imagion Biosystems Ltd (ASX: IBX) share price has rocketed 1,166% over the past 12 months due to a series of promising projects around cancer detection. The company’s bio is truly a mouthful: its principal business activities consist o...

Imagion Biosystems CEO Robert Proulx speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

Yesterday we dwelled on the notion that China’s aggressive trade tactics against Australia are in response to Western military manoeuvres. Things aren’t going to cool down anytime soon. ABC News reports that Australia is going to join ‘quad...

By Peter Switzer, Switzer Report Lots of smaller companies I like One thing I’ve personally learnt this year is the power of small cap companies to drive your portfolio’s value higher. This revelation makes me even more committed to the ide...

The capital raising wave shows no sign of crashing with August’s total coming in at $4.7bn. Once again resources companies raised more than any other sector — $163m of the $296m raised by companies with market capitalisations below $100m. F...

A quick wrap of the ASX’s key winners and losers on Thursday, August 13. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 815 stocks rose, 553 declined and...

A quick wrap of the ASX’s key winners and losers on Wednesday, August 12. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 493 stocks rose, 880 declined an...

A quick wrap of the ASX’s key winners and losers on Wednesday, July 22. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 630 stocks rose, 765 declined and...

Research by the University of Sydney has demonstrated that iron oxide nanoparticles developed by Imagion Biosystems (ASX: IBX) can enable low-field magnetic resonance imaging and could potentially reduce the costs and accessibility of MRI p...

New research indicates Imagion Biosystems’ (ASX: IBX)  imaging particles could bring down Tesla — in MRIs that is, not the car brand. A University of Sydney study shows Imagion’s iron oxide nanoparticles enable low-field magnetic resonance...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

A quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 576 declined and 819 were u...

Health Minister Greg Hunt has revived a long-standing plan to turn Australia into a “one stop shop” for clinical trials, saying he will ask the National Cabinet to prioritise reforms around ethical approval processes. Industry groups are pu...

Pitt Street Research sees a re-rating on the cards for Imagion Biosystems, which has secured strong financing through multiple avenues By Pitt Street Research An innovative medical device company Imagion Biosystems ((IBX)) is an Australian...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Now invest...

Cancer detection company Imagion Biosystems (ASX: IBX) has signed a collaboration agreement with global medical technology firm Siemens Healthineers to explore the use of Imagion’s MagSense nanoparticles as a contrast agent in magnetic reso...

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

A quick wrap of the key winners and losers on Tuesday, May 12. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Code Company Price % Change Volume...

Imagion Biosystems (ASX:IBX) has announced the appointment of Dianne Angus to its board of directors. The company, which is focused on the earlier detection of cancer, said...

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

Peter Switzer is joined by the CEO of medical imaging company Imagion Biosystems (IBX), Robert Proulx.

Melbourne-based Imagion Biosystems (ASX: IBX), a company focused on the earlier detection of cancer, has announced the appointment of Dr Oliver Steinbach as Vice President of Clinical and Regulatory Affairs.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

While investing in the stock market, an investor comes across various classes of assets, such as equity and bonds. When it comes to investing in equity, there are choices like large-cap, mid-cap and small cap. Investment in small-cap comes...

In the Australian health care system, three levels of government are responsible for providing universal health care- federal government, state and territory government and local government. Funding and indirect support are provided by the...

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics. Finfeed’s Jonathan J...

Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer, has been issued patent #320872 from the Government of India Patent Office for the company’s core intellectual propert...

Medical devices are one of an essential parts of health care system. These are used for accurate diagnosis of the disease and help health care professional to treat patients and improve their life quality. Medical device market in Australia...

Today is the deadline for firms to lodge their quarterly reports. These are the small cap companies that stood out for the right — and wrong — reasons.   Imagion Biosystems (ASX:IBX) +10% Many companies tackling cancer have a net cash outfl...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim interviews Michael Harsh, non-executive director...

Medicinal cannabis stock Althea (ASX:AGH) had a mixed bag of news for investors in its market update this morning. The company said patient numbers for its prescription medicinal cannabis products in Australia are on track to reach 4,000 by...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Imagion Biosystems: Breakthrough Device By Pitt Street Research An innovative medical device company   Imagion Biosystems ((IBX)) is an Australian medical device company whose MagSense diagnostic imaging technology, currently in early stage...

Interview with Bob Proulx, CEO Imagion Biosystems By Pitt Street Research Imagion Biosystems: Breakthrough imaging technology   We spoke with Bob Proulx, CEO Imagion Biosystems ((IBX)), about Imagion's revolutionary MagSense imaging technol...

ASX code: IBX Market cap: $12.95m Share price: 4c Shares on issue: 323,705,324 Chairman and CEO: Bob Proulx Board*: Bob Proulx, Michael Harsh, Jovanka Naumoska, Bronwyn Le Grice, Mark Van Asten, David Ludvigson *Dr John Hazle resigned in la...

In light of the volatility that has rocked global equities markets including the ASX, Finfeed felt it was timely to assess the damage on a sector by sector basis. What’s more, we have come up with six stocks that appear to have plenty going...

Event: Possible MRI applications for MagSense Finfeed noted this morning that Imagion Biosystems’ (ASX:IBX) anti-HER2 nanoparticles used in Imagion’s MagSenseTM technology, which provide specific targeting of cancerous cells, may also have...

Shares in Imagion Biosystems (ASX:IBX) have increased approximately three-fold since June on the back of significant developments with its early stage cancer detection technologies. However, they could get a further boost on Monday after th...

According to Imagion Biosystems (ASX:IBX) CEO, Robert Proulx, advancements in imaging have been slow, with no real progress made for half a century. Imagion is looking to redress that balance and speaks with Finfeed about the cancer diagnos...

Through the filing of a Pre-Submission with the U.S. Food and Drug Administration (FDA), MedTech company Imagion Biosystems (ASX:IBX) has taken its first step towards gaining approval to commence its first-in-human study into its non-invasi...

Imagion Biosystems (ASX:IBX) says it has filed pre-submission with the US Food and Drug Administration (FDA), the first step in gaining approval to commence its first-in-human study.

Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe...